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Abstract 17 
Background: Intravenous colistimethate sodium (CMS) is used to treat infections 18 
with multi-resistant Gram-negative bacteria. Optimal dosing in patients undergoing 19 
continuous renal replacement therapy (CRRT) is unclear.  20 
Materials/methods: In a prospective study, we determined CMS and colistin 21 
pharmacokinetics in 10 critically ill patients requiring CRRT (8 underwent continuous 22 
venovenous hemofiltration (CVVHD), median blood flow 100 ml/min). Intensive 23 
sampling was performed on treatment day 1, 3 and 5 after a 9 MU intravenous CMS 24 
loading dose (6 MU if body weight < 60 kg) with a consecutive 8-hourly 3 MU 25 
(respectively 2 MU) maintenance dose. CMS and colistin were determined by liquid 26 
chromatography with mass spectroscopy. A model-based population 27 
pharmacokinetic analysis incorporating CRRT settings was applied to the 28 
observations. 29 
Results: Sequential model building indicated a monocompartmental distribution for 30 
both CMS and colistin, with interindividual variability in both volume and clearance. 31 
Hematocrit was shown to affect the efficacy of drug transfer across the filter. CRRT 32 
clearance accounted for on average 41% of total CMS and 28% of total colistin 33 
clearance, confirming enhanced elimination of colistin compared to normal renal 34 
function. Target colistin steady state trough concentrations of at least 2.5 mg/L were 35 
achieved in all patients receiving 3 MU 8-hourly. 36 
Conclusion: A loading dose of 9 MU followed after 8 h by a maintenance dosage of 37 
3 MU 8 hourly independent of body weight is expected to achieve therapeutic colistin 38 
concentrations in patients undergoing CVVHD using low blood flows. Colistin 39 
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therapeutic drug monitoring might help to further ensure optimal dosing in individual 40 
patients. 41 
42 
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Introduction 43 
Colistin is a polymyxin antibiotic with concentration dependent bactericidal properties 44 
against a variety of Gram-negative species including Pseudomonas aeruginosa, 45 
Klebsiella spp., Enterobacter spp. and Acinetobacter spp.. Colistimethate sodium 46 
(CMS) is the inactive prodrug of colistin, bearing methanesulfonate residues linked to 47 
its five amine radicals. It is commercially available as Colistin® (1) and is usually 48 
used to treat multidrug-resistant strains. After intravenous administration, CMS is 49 
partially hydrolyzed (30-40%) into the active form colistin and to sulfomethylated 50 
derivatives, while two-thirds of the prodrug dose are renally excreted unchanged by 51 
glomerular filtration (2, 3). Colistin`s bioavailability is therefore limited by what could 52 
be considered a type of “renal first-pass effect”. Renal clearance of CMS in healthy 53 
volunteers approximates 100 ml/min (4). Conversely, the renal excretion of colistin 54 
itself is modest, due to active tubular reabsorption (3). In critically ill patients, 55 
Karaiskos and colleagues found the renal clearance of colistin to be not significantly 56 
different from zero (5). In patients with renal impairment, a larger fraction of CMS is 57 
available for transformation into colistin and both agents accumulate (6, 7), so that a 58 
significant dosage reduction is needed (8). The two major dose-dependent toxic 59 
effects of colistin are nephrotoxicity due to acute tubular necrosis and neurotoxicity 60 
(9). 61 
Critically ill patients may develop acute or acute-on-chronic renal failure requiring a 62 
period of continuous renal replacement therapy (CRRT). Although pharmacokinetic 63 
studies and dosing recommendations for CMS in critically ill patients with normal or 64 
impaired renal function exist, there are only a few systematic studies of the 65 
pharmacokinetics of CMS and colistin in patients undergoing CRRT (10-13). Dose 66 
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recommendations in these patients therefore differ widely and there is evidence that 67 
certain recommendations might lead to under-dosing (14). CMS and colistin have 68 
molecular weights of 1750 and 1155 Dalton respectively, meaning they are small 69 
enough to pass through haemodiafiltration high flux membranes. Protein-binding of 70 
colistin is dependent on drug concentration and ranges between 10 and 50% in 71 
animals (15), which further enables the drug to be eliminated by CRRT. Similar 72 
protein binding values have been observed in critically ill patients (16). CMS and 73 
colistin are therefore filtered and dialyzed during CRRT (13). In addition, as no 74 
tubular reabsorption occurs during CRRT, colistin clearance is – as to be expected - 75 
higher than that achieved by a healthy kidney, even though filtration rates applied are 76 
usually less than half of a normal glomerular filtration rate (13).  77 
The standard dosage of CMS for a 70 kg patient with normal renal function is 9 78 
million international units (MU) per day, divided in 2-3 doses. In the USA, dosages 79 
are usually expressed in mg of colistin base activity, with a conversion factor of 80 
33 mg for 1 MU, which corresponds to 80 mg of CMS. Previous studies have shown 81 
that reduced CMS doses ranging from 1.8 MU every 48 h to 0.9 MU every 8 h in 82 
patients undergoing continuous venovenous hemodiafiltration (CVVHDF) were 83 
associated with insufficient steady state colistin concentrations (Cssav) ranging from 84 
0.7 mg/L to 1.7 mg/L (10, 12, 14). These values are below the suggested target Cssav 85 
of 2.0 - 2.5 mg/L for susceptible bacteria with a minimal inhibitory concentration (MIC) 86 
of <0.5 mg/L (12, 17-19). Minimum inhibitory concentrations for Gram-negative 87 
bacteria such as Acinetobacter baumannii and P. aeruginosa are >1 mg/l (both 88 
breakpoints 2 mg/l (20)).  89 
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Based on those studies, some authors suggest that a higher dosage is required to 90 
achieve therapeutic colistin concentrations in patients undergoing CVVHDF. A recent 91 
study of 8 patients undergoing CVVHDF (dialysate fluid rate 1–1.5 L/h) showed that 92 
the median peak colistin concentrations after a loading dose of 9 MU was 1.55 mg/l, 93 
and during maintenance therapy with 4.5 MU every 12 h a Cssav of 1.72 mg/L was 94 
achieved (13).  95 
These data indicate significant extracorporal clearance by CRRT and support the 96 
suggestion for higher dosages of CMS in critically ill patients undergoing CVVHDF, in 97 
order to avoid underdosing and subsequent therapeutic failure. Recent studies 98 
propose a CMS loading dose of 6-12 MU in critically ill patients in order to achieve 99 
effective colistin plasma concentrations from the first treatment day (13, 16, 19, 21). 100 
A loading dose of 9 MU has been shown to be well tolerated without significant renal 101 
or neurotoxicity in a study including 22 patients with normal renal function (21).  102 
The main objective of our study was therefore to characterize the population 103 
pharmacokinetics of intravenous CMS and colistin in patients undergoing CRRT and 104 
receiving the standard dosage of CMS, predicted to achieve therapeutic 105 
concentrations in this situation according to current knowledge. Secondary study 106 
objectives were to assess clinical outcomes and drug-related adverse events.  107 
  108 
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Results 109 
Eleven patients aged between 29 and 70 years were included in the study.  One 110 
patient was subsequently excluded due to bleeding and multiple blood transfusions 111 
that lead to incorrect colistin plasma concentrations.  This left ten patients for whom 112 
data were available for analysis. Patients 5 & 6 underwent CVVHDF; all other 113 
patients underwent CVVHD. Further patient characteristics including the CMS 114 
dosages administered and the settings of CRRT are shown in Table 1. The loading 115 
dose was sampled in 3 patients whereas in the remaining patients CMS was started 116 
or continued with a maintenance dose when colistin treatment was already initiated at 117 
inclusion of the patient.   118 
CMS and colistin population pharmacokinetic profiles 119 
A satisfactory description of observations was obtained by fitting the 6-compartment 120 
model described with NONMEM®. Individual curve-fittings of patients` measured 121 
CMS and colistin concentrations are shown in Figure 2 (see Fig. S1 for a logarithmic 122 
display). Sequential model building indicated that a model assuming interindividual 123 
variability in terms of volume and clearance parameters (VCMS, VCol, CLM CMS and 124 
CLM Col), fitted the data better than a model assuming constant population values for 125 
these parameters. Conversely, the results did not show evidence for interindividual 126 
differences in sieving coefficients (SCMS and Scol). We found no indication that age, 127 
body weight, sex or albumin had a role to play as covariates. Conversely, the 128 
inclusion of hematocrit (Ht) as a covariate affecting the efficacy of blood transfer 129 
(Qblood) in and out of the filter improved the model significantly. Diagnostic plots in 130 
arithmetic and logarithmic form (Figures S2 and S3, respectively) visualized model 131 
validation.   132 
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The primary pharmacokinetic estimates corresponding to our final model, namely 133 
metabolic clearance, distribution volumes and sieving coefficients for CMS and 134 
colistin are given in Table 2, along with the maximum likelihood individual parameters 135 
corresponding to each study patient. In accordance with its physicochemical 136 
characteristics, CMS had a higher sieving coefficient and a smaller volume of 137 
distribution than colistin (Table 2).  138 
The primary pharmacokinetic parameters enabled the calculation of derived 139 
parameter values such as cumulative areas und the curve, fractions excreted through 140 
CRRT, total clearances and steady-state trough concentrations of both CMS and 141 
colistin (Table 3). CMS-had a greater clearance (both total and through CVVHD) than 142 
colistin, with consequent longer colistin half-life and higher steady-state trough 143 
concentrations. CMS was more efficiently removed by CVVHD than colistin, as 144 
reflected by CRRT clearance accounting for on average 41% of the total CMS and 145 
28% of the total colistin clearance, respectively (Table 3). 146 
Target colistin Cssav of 2.5 mg/L was achieved in all patients who received a 147 
maintenance dose of 3 MU but in none of the patients who received a maintenance 148 
dose of 2 MU (Table 3).   149 
Adverse Events 150 
Overall, no alarming drug accumulation was observed over the five treatment days 151 
(Figure 2 - one exception being possibly Patient 8) and no adverse events 152 
attributable to CMS or colistin were recorded.   153 
Patient outcomes 154 
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Infection control (as evidenced by a reduction in inflammatory markers such as C-155 
reactive protein and leucocyte count) was achieved in three patients and microbial 156 
cure in one patient. However, 7 of the 10 included patients experienced a fatal 157 
outcome of their severe illness. Renal function improved in 4 patients (moderate 158 
renal impairment, no renal replacement therapy) and one patient remained on 159 
intermittent hemodialysis.  160 
 161 
Discussion  162 
In a population pharmacokinetic study of intravenous CMS in patients undergoing 163 
CRRT, we found that a compartmental model incorporating CRRT settings best 164 
described the disposition of CMS and colistin. This population analysis revealed a fair 165 
degree of interindividual variability in volume and clearance parameters (VCMS, VCol, 166 
CLM CMS and CLM Col), as is often found for therapeutic drugs undergoing metabolic 167 
biotransformations. This variability was not significantly explained by age, body 168 
weight, sex and serum albumin concentration, as these covariates did not improve 169 
model performance. However, hematocrit improved the model significantly, a finding 170 
consistent with its direct impact on drug transfer from the patient’s body to the CRRT 171 
filter cartridge. It is also remarkable to observe that the model did not indicate 172 
between-patient variability in either sieving coefficients of CMS and colistin. This is 173 
not surprising for CMS, a highly hydrophilic prodrug that is poorly bound to plasma 174 
proteins. As our patients had little heterogeneity regarding their circulating albumin 175 
concentrations (Table 1), no effect of this covariate on colistin sieving could be 176 
observed, even though colistin is more extensively protein-bound than CMS. We 177 
propose that our findings will enable future optimal CMS dosing in patients 178 
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undergoing CRRT to achieve adequate antibacterial efficacy, to avoid the emergence 179 
of colistin-resistant organisms (22) and to minimize toxicity. 180 
In their population pharmacokinetic study of CMS in critically ill patients not 181 
undergoing CRRT, Karaiskos and colleagues similarly found that a model with 182 
several compartments (5 in total) best described their data (5). 183 
In patients with normal renal function, renal clearance accounts for two-thirds of CMS 184 
clearance and almost none of colistin clearance (3, 4). By comparison, in the present 185 
study CRRT clearance accounted for 41% of CMS clearance and 28% of colistin 186 
clearance. In the study performed by Karaiskos, CVVHDF clearance of CMS and 187 
colistin were estimated at 60% and 62% respectively (13). The lower clearance found 188 
in our study may be related to the lower blood flows (100 – 127 ml/min compared to 189 
100 – 180 ml/min). The significant colistin clearance during CVVHDF is attributable to 190 
the absence of tubular reabsorption. In other words, while CMS clearance is reduced 191 
in renal impairment managed with CRRT, colistin clearance is increased. 192 
Consequently, higher doses of intravenous CMS are required, as already noted in 193 
some current guidelines such as the Sanford Guide to Antimicrobial Therapy, which 194 
recommends a daily CMS dose of 13 MU (442 mg colistin base) (23), but not in the 195 
Food and Drug Administration approved drug label (8).   196 
Target colistin Cssav of 2.5 mg/L for susceptible bacteria with a minimal inhibitory 197 
concentration (MIC) of <0.5 mg/L (16) was achieved in all patients who received a 198 
maintenance dose of 3 MU but in none of the patients who received a maintenance 199 
dose of 2 MU (Table 3). In the study by Karaiskos and colleagues in which 4.5 MU 200 
were administered every 12 hours, 24 hours after receiving a 9 MU loading only half 201 
achieved steady-state colistin concentrations 6 h post dose of 1.72 mg/l or higher 202 
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(13). A reason for this discrepancy is the higher CVVHDF clearance in the above-203 
mentioned study. A further explanation might be that the 6-h post dose concentration 204 
as measured by Karaiskos and colleagues does not reflect the peak concentration 205 
attained before the next CMS dose as accurately as the pre-dose sample which was 206 
analyzed in our study (8-h post-dose).   207 
In the study by Nation and colleagues, which included data from 9 patients 208 
undergoing CRRT (average blood flow 160 ml/min, 9 MU CMS loading dose and 13 209 
MU daily maintenance dose) (19), CMS clearance due to CRRT was 1.57 L/h, which 210 
was identical to our finding. Colistin CRRT clearance, however, was higher (2.68 L/h, 211 
compared to 0.796 L/h in our study). In the above-mentioned study by Karaiskos and 212 
colleagues of 8 patients undergoing CRRT (blood flow 100 – 180 ml/min, 9 MU CMS 213 
loading dose and 9 MU daily maintenance dose), CMS and colistin CRRT clearances 214 
were 1.17 L/h and 2.09 L/h respectively (13). Taken together, these findings suggest 215 
that CMS-clearance may be filter-limited, while Colistin-CRRT clearance depends on 216 
blood-flow. Two other studies both using 9 MU daily maintenance doses and a blood 217 
flow of 120 ml/min (comparable to the present study) in seven and four patients 218 
undergoing CRRT (11, 24) showed colistin CRRT clearances of about 0.7 L/h, which 219 
compared to our findings.   220 
For daily clinical practice, we therefore suggest starting CMS in patients that are 221 
undergoing CVVHD using low blood flows with a loading dose of 9 MU and a 222 
maintenance dose of 3 MU every 8 hours (independent of body weight), so that 223 
therapeutic colistin concentrations have a high likelihood of being achieved. As Css 224 
av only depends on clearance (and not volume of distribution), the maintenance dose 225 
does not need to be weight-adjusted.   226 
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The present study has some limitations. Although prospective in design, patients 227 
were included based on their clinical need for intravenous CMS and concurrent 228 
CRRT. This resulted in a modest sample size and inability to perform PK-sampling 229 
after a loading dose in the setting of CRRT in every case. Despite satisfactory global 230 
diagnostics (Fig. S2 and S3 in supplementary material), isolated misfit points are 231 
observed, most likely resulting from technical issues such as inaccuracies in dose 232 
preparation, sample collection, or CVVHD efficacy due to filter clogging or clotting. A 233 
further limitation is the missing data regarding hematocrit. However, the available 234 
data showed a small spread, so we are confident that using the average value for the 235 
group as a whole did not significantly affect the results. 236 
In conclusion, CMS and colistin disposition after intravenous application is complex 237 
and CRRT substantially increases the clearance of colistin compared to normal renal 238 
function. A loading dose of 9 MU and a maintenance dosage of 3 MU every 8 hours 239 
independent of body weight are expected to quickly achieve and maintain therapeutic 240 
colistin concentrations in patients undergoing CRRT with low blood flows. We 241 
suggest starting the maintenance dosage 8 hours after administering the loading 242 
dose. Furthermore, this dosage was not associated with adverse events. Therapeutic 243 
drug monitoring of CMS and colistin might further ensure optimal dosing, particularly 244 
in problematic situations such as co-morbid hepatic insufficiency or inefficient CRRT.   245 
 246 
Materials and Methods 247 
The study was performed in accordance with the Declaration of Helsinki and its 248 
amendments, International Conference on Harmonization (ICH) Good Clinical 249 
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Practice (GCP) guidelines and applicable national laws and regulations. Ethical 250 
approval for the study was granted by the internal review boards of the participating 251 
centers (ZH 2012-0451, CER-VD 197/14 and EKNZ 2014-213) and permission to 252 
conduct the study was given by the national authority (Swissmedic, 2013DR1132).  253 
The study was registered at ClinicalTrials.gov (NCT02081560). All patients enrolled 254 
in the study gave their written, informed consent if able to do so. When patients were 255 
not able to give consent themselves, the protocol for studies in adult patients unable 256 
to give consent was followed, in accordance with the internal review boards’ 257 
permission.  258 
Study design 259 
The study is an investigator-driven, multi-center, prospective, non-randomized, open 260 
label pharmacokinetic investigation of CMS in critically ill patients requiring CVVHDF.  261 
The participating centers were University Hospital Zurich, University Hospital 262 
Lausanne and University Hospital Basel. 263 
Study patients 264 
Patients were eligible for enrolment if they fulfilled the following criteria: male or 265 
female aged 18 years or older, hospitalized on the intensive care unit (ICU) with a 266 
clinical necessity for both, treatment with CMS (for a proven severe infection with 267 
multi drug resistant Gram-negative bacteria susceptible to colistin with no standard 268 
first-line treatment available) and continuous venovenous renal replacement therapy.  269 
Study drug  270 
Colistin® (colistimethate) was delivered in dry-powder form together with an ampoule 271 
of 3 ml isotonic saline solvent (1). One bottle of Colistin® contains 1 million units 272 
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(MU) of sodium colistimethate. Colistin® was dispensed from the local hospital 273 
pharmacy and stored on the intensive care units. CMS maintenance dosing was set 274 
to 3 MU (=240 mg) every 8 hours (total 9 MU/d = 720 mg/d) after administration of a 275 
loading dose of 9 MU. In patients with a low body weight (≤ 60 kg), the dose was 276 
reduced to a loading dose of 6 MU and to a maintenance dose of 2 MU every 8 277 
hours. The CMS solution was to be administered intravenously over 30 minutes. For 278 
pharmacokinetic calculations, CMS doses in mg and concentrations in mg/L were 279 
converted into colistin equivalents using a conversion factor of 1155/1750 = 0.66.  280 
CRRT procedures 281 
Continuous venovenous hemodialysis (CVVHD) was performed in all but one patient 282 
with Prismaflex ST150 (Gambro AB, Lund, Sweden) using the capillary hemofilter 283 
AN69 ST (acrylonitrile-sodium-methyl sulfonate, surface area 1.5 m2) and infusing 284 
citrate as the anti-coagulation agent. Continuous venovenous hemodiafiltration 285 
(CVVHDF) in a ratio set 1:1 was performed with Multifiltrate (Fresenius Medical Care, 286 
Homburg, Germany) using the capillary hemofilter AV 1000s (polysulfone, surface 287 
area 1.8 m2). Post-dilution mode was performed for one patient.   288 
Pharmacokinetic sampling 289 
Intensive pharmacokinetic (PK) sampling over one dosing interval (8 hours) was 290 
scheduled on treatment day 1 after the CMS loading dose and day 3 (after the 7th 291 
dose). Intensive PK sampling involved blood samples taken from the pre-filter (“filter 292 
afferent”) line at 0, 0.5, 1, 2, 3, 6, and 8 hours after CMS dosing and from the post-293 
filter line at 1 and 8 hours after dosing. Dosing and sampling times were precisely 294 
recorded, along with the relevant settings of CRRT (blood and hemofiltration flow 295 
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rates). Blood was collected in tubes containing citrate. Plasma was obtained by 296 
centrifugation of whole blood samples within 30 minutes and then stored at -80°C 297 
until analysis to prevent degradation of CMS into colistin ex-vivo (25). Peak and 298 
trough blood concentrations in the pre-filter line were determined on day 5. Patients 299 
already on colistin treatment at study entry underwent PK sampling on treatment day 300 
3 (7th dose) and on day 5 if already undergoing CRRT. In patients starting CRRT 301 
during established treatment with Colistin®, the dosage was adapted according to 302 
the protocol, the first PK sampling was performed on the third day of CRRT, and the 303 
study continued according to the protocol. Patients were monitored daily for any 304 
abnormalities in blood biochemistry and hematology values and for signs of adverse 305 
drug effects.   306 
Determination of plasma CMS and colistin concentrations 307 
Plasma CMS and colistin concentrations were determined by high-throughput 308 
hydrophilic interaction chromatography coupled to tandem mass spectrometry 309 
according to the method described by Mercier and colleagues (26). Briefly, the 310 
method was first applied to the native plasma samples to determine colistin 311 
concentration; then the samples underwent acidic hydrolysis for 4h to extensively 312 
transform CMS into colistin, colistin was determined again and the difference was 313 
assumed to reflect CMS (including intermediate metabolites partially hydrolyzed). 314 
The results of CMS were accordingly expressed in mg/L of colistin. All analyses were 315 
performed at the University Hospital Lausanne.  316 
Pharmacokinetic analysis 317 
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A model-based pharmacokinetic analysis was performed using NONMEM® (version 318 
7.4, 2017, ICON plc, Dublin 18, Ireland) with NMTRAN and the PREDPP subroutine 319 
ADVAN6. The disposition of CMS and colistin was described using a 6-compartment 320 
model with first-order transfer rates describing the metabolic transformation of CMS 321 
into colistin, the metabolic elimination of colistin and the exchanges of both 322 
compounds occurring within the CRRT apparatus (Fig. 1). The systemic distributions 323 
of CMS and colistin were assumed to be rapid, corresponding to a single-324 
compartment volume each (VCMS and VCol). The fraction of the CMS dose escaping 325 
elimination through CRRT was assumed to be completely transformed into colistin 326 
through metabolic clearance (CLM CMS); then colistin, in turn, was considered to be 327 
eliminated through both CRRT and metabolic clearance (CLM Col). Both compounds 328 
were assumed to be transferred into a CRRT filter of fixed volume (Vfilter = 0.2 L) at 329 
the flow rate read on the CRRT device (Qblood), corrected for the patient’s hematocrit 330 
(1 - Ht), set to the average HT value (0.25) when unknown. Non-filtered amounts of 331 
CMS and colistin were driven back into the patient’s circulation with the same blood 332 
flow, while filtered amounts passed into the fixed volume filter cartridge (Vcartridge = 0.3 333 
L), continuously rinsed with the effluent flow rate read on the CRRT device (Qeffl). 334 
Sieving coefficients were assumed to characterize the filter permeability for CMS and 335 
colistin (SCMS and Scol), multiplying Qeffl to give the respective filtration clearances.  336 
The model, expressed as a set of differential equations, was fitted to the data using 337 
first order conditional estimation with interaction between inter-patient and residual 338 
variabilities. Classical equations were used for relating model microconstants (k12, 339 
k13, k31, k20, k24, k42, k35, k46, k50 and k60) to the estimated parameters, i.e. VCMS, VCol, 340 
CLM CMS, CLM Col, SCMS and Scol, given the known parameters, i.e. Vfilter, Vcartridge, Qblood, 341 
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Ht and Qeffl. Interindividual variability in estimated parameters was described using an 342 
exponential error model (namely j = ·e
j, where j is the individual pharmacokinetic 343 
parameter of the jth individual,  is the geometric average population value and j is a 344 
random effect normally distributed around a zero mean with a variance of 2). The 345 
inclusion of variability was tested on each parameter for improvement of the model, 346 
based on the change in objective function (OF) resulting from the addition of a 347 
model term (which approximately follows a 2 distribution and can be regarded as 348 
statistically significant at the level p<0.05 if it exceeds 3.8 for one additional 349 
parameter). Residual error was described using a mixture of exponential plus additive 350 
distributions; there was no indication for different magnitudes of variability between 351 
the types of samples. The influence of covariates such as age, sex and body weight 352 
on distribution volumes and metabolic clearances, and plasma albumin on sieving 353 
coefficients was explored graphically and tested sequentially for inclusion in the 354 
model, based on the OF criterion. The following derived parameters were computed 355 
numerically from individual parameter estimates obtained by model fitting: cumulative 356 
areas under plasma concentration curves (AUCCMS and AUCCol), trough 357 
concentrations at steady-state under maintenance dosage (CSS min CMS and CSS min Col) 358 
and total amounts excreted by CRRT (Ae CMS and Ae Col). Taking into account 359 
cumulative CMS doses, we estimated the fractions of dose eliminated by CRRT (Fe 360 
CMS and Fe Col), the hemofiltration (CLCRRT CMS and CLCRRT Col) and total clearances 361 
(CLtot CMS and CLtot Col), and the apparent half-lives deduced from corresponding 362 
distribution volumes (t½ CMS and t½ Col).  363 
Model validation was based on diagnostic goodness-of-fit plots and on the 364 
examination of standard errors and correlation matrix of the estimates. Figures were 365 
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elaborated with GraphPad Prism (Version 7 for Windows, 2017, GraphPad Software, 366 
San Diego California USA). The population pharmacokinetic model developed for this 367 
study may be accessed on the DDMoRe Model Repository at: 368 
http://repository.ddmore.foundation//model/DDMODEL00000295.  369 
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Table 1  469 
Patient description: age, body weight, sex, loading dose, maintenance dose, number of maintenance doses administered, average blood flow and effluent rate through CRRT device. 470 
Alb.: albumin, CV:  coefficient of variation, CVVHD: continuous venovenous hemodialysis, CVVHDF:  continuous venovenous hemodiafiltration, Dload: CMS loading dose, Dmaint: CMS 471 
maintenance dose, Dmaint tot : CMS total number of maintenance doses, gmean:  geometric mean, Hct: hematocrit, MIC:  minimum inhibitory concentration (ranges indicate results of 472 
different isolates tested over time), na: not available, Qblood : blood flow,  Qeffl,  effluent flow rate, VAP: ventilator-associated pneumonia 473 
 474 
 475 
 476 
ID Age 
(y) 
Wt 
(kg) 
Sex Diagnoses and indication for colistin Colistin 
MICs 
Hct Alb 
(g/l) 
Dload 
(MU) 
Dmaint 
(MU) 
Dmaint tot 
(MU) 
CRRT Qblood 
(mL/min) 
Qeffl 
(L/h) 
Outcome 
1  60 65 M Acute lymphoblastic leukaemia, 
pneumonitis, P. aeruginosa bacteraemia 
 
<4 
na na 9 3 18 CVVHD 100 2180 Infection controlled 
2 51 73 M Sepsis with multiresistant P. aeruginosa, 
multiorgan failure 
na na na 9 3 7 CVVHD 100 2000 Died  (multiorgan 
failure) 
3 29 82 M Polytrauma, P. aeruginosa pneumonia 
and septic shock 
0.75-1 0.24 22 9 3 15 CVVHD 108 2793 Infection controlled 
4 44 60 M Lung transplant, mediastinal abscess, 
acute respiratory failure (P. aeruginosa 
VAP) 
 
 
0.38 
0.33 20 2 2 14 CVVHD 122 3071 Infection controlled  
 
5 34 60 M Cycstic fibrosis, liver cirrhosis, P. 
aeruginosa pneumonia and septic shock 
0.047-0.5 0.27 28 2 2 24 CVVHDF 120 2479 Died (pulmonary 
hemorrhage) 
6 47 66 M HIV, pulmonary hypertension, PCP 
pneumonia, acute respiratory distress 
syndrome, P. aeruginosa and 
Citrobacter freundii VAP 
 
 
1 
0.125 
0.23 21 9 3 12 CVVHDF 127 2473 Died (respiratory 
failure) 
7 67 60 M Cholangitis, septic shock (E.coli ESBL), 
acute respiratory distress syndrome   
na 0.26 22 6 2 6 CVVHD 118 2250 Died (cholangitis) 
 70 85 M Pancreas carcinoma, post-operative 
septic shock, P. aeruginosa VAP 
 
1.5 
na na 3 3 19 CVVHD 100 2278 Died (multiorgan 
failure) 
10  44 46 F Lung transplant, P. aeruginosa 
tracheobronchitis 
0.125 0.23 20 2 2 22 CVVHD 80 1601 Died (cause unknown) 
after Infection cleared 
11 68 60 F Necrotising pancreatitis, ventilator-
associated pneumonia, severe sepsis  
na 0.25 24 9 3 10 CVVHD 100 2652 Died (multiorgan 
failure) 
Summary statistics               
mean 50.4 65.7          108 2378  
SD 16.0 11.6          14 416  
median 49.0 62.5          104 2376  
min 24.0 46.0          80 1601  
max 70.0 85.0          127 3071  
gmean 47.8 64.8          107 2343  
CV 34% 18%          13% 18%  
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Table 2  477 
Population averages and coefficients of variation (CV), followed by maximum 478 
likelihood individual estimates of primary pharmacokinetic parameters: metabolic 479 
clearances, distribution volumes and sieving coefficients for CMS and colistin. 480 
Residual error is described by a mixed exponential and additive error model, with 481 
respectively a coefficient of variation of 22.2% and a standard deviation (SD) of 0.459 482 
mg/L. CLM CMS: metabolic clearance of CMS, VCMS: volume of distribution of CMS, S CMS: CMS 483 
sieving coefficient, CLM Col: metabolic clearance of colistin, V Col: volume of distribution of 484 
colistin, S Col Colistin sieving coefficient, Pop: population SE: standard error, geomean: 485 
geometric mean. 486 
   CMS   Colistin  
 
 CLM CMS VCMS S CMS CLM Col V Col S Col 
 
 (L/h) (L) 
 
(L/h) (L) 
 Pop estimate  2.31 12.1 1.05 1.93 70.1 0.454 
SE  0.412 1.42 0.0667 0.444 15.5 0.0181 
Pop CV  52% 36% - 67% 50% - 
SE  0.162 0.106 - 0.218 0.127 - 
Patient estimates        
 
1 2.34 12.2 1.050 3.18 35.5 0.454 
 2 7.33 28.3 1.050 2.50 69.0 0.454 
 3 2.41 11.7 1.050 1.81 84.8 0.454 
 4 1.98 8.9 1.050 2.01 85.4 0.454 
 5 2.41 11.9 1.050 2.14 73.3 0.454 
 6 3.12 14.8 1.050 1.54 67.6 0.454 
 7 1.62 8.0 1.050 2.49 70.8 0.454 
 8 1.46 9.6 1.050 1.38 123.6 0.454 
 10 2.79 10.1 1.050 4.09 73.1 0.454 
 11 1.13 13.4 1.050 0.54 39.0 0.454 
mean  2.66 12.9 1.050 2.17 72.2 0.454 
SD  1.75 5.8 
 
0.99 24.6 
 median  2.37 11.8 
 
2.07 72.0 
 min  1.13 8.0 
 
0.54 35.5 
 max  7.33 28.3 
 
4.09 123.6 
 geomean  2.32 12.1 
 
1.93 68.3 
 CV  75% 48% 
 
51% 36% 
  487 
 488 
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Table 3  489 
Secondary pharmacokinetic parameters derived from individual estimates of Table 2: cumulative areas under curve (AUC), fractions 490 
excreted through CRRT (Fe), total clearances (CLtot), trough concentrations at steady-state (Css min) and average concentrations at 491 
steady-state (Css av) of CMS and colistin. SD: standard deviation, CV: coefficient of variation. For dose-dependent parameters (AUC 492 
and CSS min), means, SD, medians and ranges were calculated only with data from patients receiving a maintenance regimen of 3 MU 493 
every 8 h (marked by *).  494 
ID    CMS       Colistin    
 
AUCCMS Fe CMS CLtot CMS CLCVVHD CMS  t½ CMS CSS min CMS CSS av CMS AUCCol Fe Col CLtot Col CLCVVHD Col t½ Col CSS min Col CSS av Col 
 
(h·mg/L) 
 
(L/h) (L/h) (h) (mg/L) (mg/L) (h·mg/L) 
 
(L/h) (L/h) (h) (mg/L) (mg/L) 
1* 865 0.393 3.850 1.513 2.20 1.26 5.15 506 0.203 3.993 0.811 6.16 2.58 3.01 
2* 181 0.163 8.766 1.429 2.24 0.58 2.26 404 0.230 3.283 0.755 14.57 4.63 5.05 
3* 658 0.434 4.265 1.851 1.91 0.86 4.65 548 0.348 2.899 1.009 20.29 3.69 3.87 
4 (406) 0.484 3.840 1.859 1.61 (0.34) (3.44) (251) 0.338 3.204 1.083 18.48 (1.91) (2.13) 
5 (621) 0.424 4.183 1.774† 1.98 (0.62) (3.16) (480) 0.299 3.124 0.934† 16.26 (2.28) (2.44) 
6* 479 0.361 4.889 1.765† 2.10 0.83 4.05 590 0.370 2.534 0.938† 18.47 4.64 5.00 
7 (312) 0.459 2.996 1.375 1.85 (0.58) (4.41) (163) 0.163 3.110 0.507 15.79 (1.87) (2.30) 
8* 1044 0.511 2.990 1.528 2.24 1.60 6.63 607 0.329 2.511 0.826 34.12 3.92 3.85 
10 (608) 0.290 3.933 1.141 1.78 (0.51) (3.36) (361) 0.128 4.702 0.602 10.78 (1.75) (1.99) 
11* 765 0.574 2.651 1.522 3.50 2.41 7.47 741 0.430 1.164 0.501 23.21 4.00 7.24 
mean 665 0.409 4.236 1.576 2.14 1.26 5.03 566 0.284 3.052 0.796 17.81 3.91 4.67 
SD 304 0.117 1.731 0.222 0.52 0.67 1.86 112 0.098 0.933 0.194 7.48 0.76 1.48 
median 712 0.429 3.892 1.525 2.04 1.06 4.90 569 0.314 3.117 0.804 17.37 3.96 4.43 
min 181 0.163 2.651 1.141 1.61 0.58 2.26 404 0.128 1.164 0.501 6.16 2.58 3.01 
max 1044 0.574 8.766 1.859 3.50 2.41 7.47 741 0.430 4.702 1.083 34.12 4.64 7.24 
geomean 583 0.390 4.003 1.559 2.09 1.12 4.70 557 0.266 2.894 0.771 16.35 3.84 4.49 
CV 52% 30% 43% 14% 25% 60% 40% 20% 37% 32% 25% 46% 20% 33% 
*  3 MU q. 8 h maintenance dose; † CLCVVHDF 495 
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Figure 1 497 
Six-compartment pharmacokinetic model describing the disposition of CMS and colistin during CRRT, and showing the sampling 498 
points (in italic). See text for parameter definitions.  499 
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Figure 2: Individual curve fitting of patients` observations (solid circles)  502 
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in arithmetic scale 503 
 504 
 505 
 506 
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